ClinicalTrials.gg
RecruitingNCT06536348Updated May 19, 2026

PARKINSON BRASIL - Database on Motor and Non-Motor Aspects of Parkinson's Disease in Brazil

An observational study in Parkinson Disease, sponsored by Federal University of Uberlandia. Recruiting at 5 sites in Brazil. Open to participants aged 18 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Federal University of Uberlandia · Observational

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Study type
Observational
Model
Other
Time perspective
Other
Enrollment
958
Ages
18 Years to 120 Years
Sex
All
01

Study summary

This is an observational, cross-sectional study with a control group, with the general objective of developing and evaluating a national database, unprecedented in Brazil, containing clinical, epidemiological, motor, and non-motor aspects of Parkinson's disease (PD). The database will be open and accessible to national and international researchers in order to contribute to the advancement of research related to PD. The aim is to collect data, in a paired way, from a control group and an experimental group. Data collection will include the application of questionnaires, the execution of motor activities, and clinical scales. Information that can identify the participants will be removed from the database for later storage in a repository. Quantitative, qualitative, and descriptive variables from the database will be estimated in order to characterise and contrast the groups studied. The results of this study will contribute to a better characterization of the staging of PD as a function of the epidemiological, motor, and non-motor aspects evaluated, as well as to the development of technologies and methods that can be applied in clinical practice.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson's disease
  • motor assessment
  • non-motor assessment
  • database
  • computer vision
  • inertial sensors
03

In context

Parkinson Disease

4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's planned enrollment of 958 is above the median of 96 across 1,085 observational studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Federal University of Uberlandia is the lead sponsor of 61 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  • Experimental group: Individuals diagnosed with Parkinson's disease
  • Control group: Individuals not having Parkinson's disease (PD) or other neurological disease that resembles PD;

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Experimental group: (i) present a neurological diagnosis of Parkinson's disease; (ii) be classified between stages I to IV of the Hoehn \& Yahr Scale; (iii) have central visual acuity equal to or greater than 20/40 (equivalent to 0.50) in each eye or equal to or greater than 20/30 (equivalent to 0.66) in one eye according to the Snellen scale.
  • Control group: (i) not having a neurological diagnosis of Parkinson's disease or other neurological disease that resembles PD; (ii) have central visual acuity equal to or greater than 20/40 (equivalent to 0.50) in each eye or equal to or greater than 20/30 (equivalent to 0.66) in one eye according to the Snellen scale.

Exclusion criteria

Exclusion Criteria:

For both groups, individuals who have other neurological or musculoskeletal diseases that interfere with the execution of the tests will be excluded.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
958 participants (estimated)
Patient registry
No

Groups and cohorts

  • Experimental group

    Group of subjects with Parkinson's disease

  • Control group

    Neurological healthy subjects

06

What researchers measure

Primary outcomes

  1. Sex

    Sex: male, female

    Time frame: 10 years

  2. Age

    Age in years

    Time frame: 10 years

  3. Length of schooling

    Length of schooling in years

    Time frame: 10 years

  4. Weight

    Weight in kg

    Time frame: 10 years

  5. Height

    Height in cm

    Time frame: 10 years

  6. Blood type

    Blood type: A+, A-, B+, B-, O+, O-, AB+, AB-

    Time frame: 10 years

  7. Economic Rating Score

    Economic rating as given by the Brazilian Economic Classification Criteria (Brazilian Criteria) - https://www.abep.org/criterioBr/01\_cceb\_2022\_eng.pdf

    Time frame: 10 years

  8. Primary ICD

    Primary disorder classification according to the International Statistical Classification of Diseases and Related Health Problems (ICD) https://www.who.int/standards/classifications/classification-of-diseases

    Time frame: 10 years

  9. Secondary ICDs

    Secondary disorder according to the International Statistical Classification of Diseases and Related Health Problems (ICD) https://www.who.int/standards/classifications/classification-of-diseases

    Time frame: 10 years

  10. Medications in use

    name and daily dose of medications

    Time frame: 10 years

  11. Family history related to the primary ICD

    Is there family history related to the primary ICD? (yes, no)

    Time frame: 10 years

  12. Date of symptom onset related to the primary ICD

    date

    Time frame: 10 years

  13. Date of diagnosis related to the primary ICD

    date

    Time frame: 10 years

  14. Current city of residence

    City of residence in Brazil

    Time frame: 10 years

  15. Current state of residence

    State of residence in Brazil

    Time frame: 10 years

  16. Civil status

    married, single, divorced, and widowed

    Time frame: 10 years

  17. Housing classification

    Housing classification by type of housing ownership rights: State-owned housing, Municipality-owned housing, Natural person's owned housing, Legal person's owned housing, Private renting, Other

    Time frame: 10 years

  18. Household size

    The number of adults and children living in a home

    Time frame: 10 years

  19. Laterality

    Laterality refers to the preference for using one side of the body over the other and is most commonly associated with hand dominance, such as being right-handed or left-handed, e.g., Right-handedness, Left-handedness, Ambidexterity, Mixed-handedness (Cross-dominance).

    Time frame: 10 years

  20. Use of technology

    Verification if the participant has had contact with one of the following devices: mobile, personal computer, mouse, webcam, keyboard, microphone, earphone.

    Time frame: 10 years

  21. Occupation

    Profession according to the Brazilian Classification of Occupation (https://www.mtecbo.gov.br/cbosite/pages/home.jsf)

    Time frame: 10 years

  22. Monthly wage

    Monthly wage in Brazilian Reais

    Time frame: 10 years

  23. Head movement amplitude

    Head movement amplitude in degrees

    Time frame: 10 years

  24. Head movement speed

    Head movement speed in degrees per second

    Time frame: 10 years

  25. Facial expression

    Facial expression evaluation according to the Facial Action Coding System (FACS)

    Time frame: 10 years

  26. Saccadic eye movement

    Speed and regularity of eye movement (degrees per second and latency in ms)

    Time frame: 10 years

  27. Smooth pursuit eye movement

    Smooth pursuit are quantified by the gain (how well the eyes follow the target in speed) and phase (distance to the target during pursuit)

    Time frame: 10 years

  28. Handwriting movement analysis

    Handwriting speed (seconds) and quality

    Time frame: 10 years

  29. MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    Clinical scale for measuring signs and symptoms of Parkinson's disease (https://www.movementdisorders.org/MDS/MDS-Rating-Scales/MDS-Unified-Parkinsons-Disease-Rating-Scale-MDS-UPDRS.htm?gad\_source=1\&gclid=CjwKCAjwnqK1BhBvEiwAi7o0X6DuHrFh3qftNQ1N9AGWMkFo4BpG6b3hAFWnoh2Dwu86DPY53ZXpKRoCBRYQAvD\_BwE) Each item of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale will be evaluated as 0: Normal; 1: Slight; 2: Mild; 3: Moderate; 4: Severe. The minimum value of the scale is 0, whereas the maximum value is 4. Higher scores mean a worse outcome.

    Time frame: 10 years

  30. Depression

    Depression measured according to the Geriatric Depression Scale (GDS) https://geriatrictoolkit.missouri.edu/cog/GDS\_SHORT\_FORM.PDF The Geriatric Depression Scale has 15 items. The minimum total score is zero, and the maximum is 15. Higher scores mean a worse outcome.

    Time frame: 10 years

  31. Visual Acuity

    Visual Acuity measured according to the Snellen test (https://www.ncbi.nlm.nih.gov/books/NBK558961/)

    Time frame: 10 years

  32. Cognition

    Cognition measured according to the Montreal Cognitive Assessment (MOCA) scale The Montreal Cognitive Assessment (MoCA) is a 30-point test. The minimum total score is zero, and the maximum is 30. Higher scores mean a better outcome.

    Time frame: 10 years

  33. Dysarthria

    Dysarthria measured according to the protocol for the evaluation of central dysartries in patients with Parkinson's Disease (https://doi.org/10.1590/S1516-18462011005000030)

    Time frame: 10 years

  34. Hand movement

    Hand movement in degrees per second

    Time frame: 10 years

07

Study locations

3 of 5 sites recruiting
  • Laboratório de Análise de Movimento e Processamento de Sinais
    Brasília, Federal District 72220-275, Brazil
    Not yet recruiting
  • Centro Universitário Araguaia (UniAraguaia)
    Goiânia, Goiás 74.223-060, Brazil
    Recruiting
  • Associação Parkinson Goiás
    Goiânia, Goiás 74265-320, Brazil
    Not yet recruiting
  • Ambulatório de Doença de Parkinson e Distúrbios do Movimento do Hospital de Clínicas de Uberlândia
    Uberlândia, Minas Gerais 38405-318, Brazil
    Recruiting
  • Núcleo de Inovação e Avaliação Tecnológica em Saúde / Centre for Innovation and Technology Assessment in Health
    Uberlândia, Minas Gerais 38408-100, Brazil
    Recruiting
08

References and documents

Publications

  • Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE. Parkinson disease. Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13. PubMed 28332488 ↗
  • World Health Organization, Parkinson disease, 2023.
  • Barbosa MT, Caramelli P, Maia DP, Cunningham MC, Guerra HL, Lima-Costa MF, Cardoso F. Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord. 2006 Jun;21(6):800-8. doi: 10.1002/mds.20806. PubMed 16482566 ↗
  • Vale TC, Barbosa MT, Resende EPF, Maia DP, Cunningham MCQ, Guimaraes HC, Machado JCB, Teixeira AL, Cardoso F, Caramelli P. Parkinsonism in a population-based study of individuals aged 75+ years: The Pieta study. Parkinsonism Relat Disord. 2018 Nov;56:76-81. doi: 10.1016/j.parkreldis.2018.06.030. Epub 2018 Jun 19. PubMed 29934195 ↗
  • Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020 Feb;36(1):1-12. doi: 10.1016/j.cger.2019.08.002. Epub 2019 Aug 24. PubMed 31733690 ↗
  • Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N, Olanow CW. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci. 2000 Oct;23(10 Suppl):S8-19. doi: 10.1016/s1471-1931(00)00028-8. PubMed 11052215 ↗
  • Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017 Aug;124(8):901-905. doi: 10.1007/s00702-017-1686-y. Epub 2017 Feb 1. PubMed 28150045 ↗
  • Dickson JM, Grunewald RA. Somatic symptom progression in idiopathic Parkinson's disease. Parkinsonism Relat Disord. 2004 Dec;10(8):487-92. doi: 10.1016/j.parkreldis.2004.05.005. PubMed 15542009 ↗
  • Cabral AM, Lora-Millan JS, Pereira AA, Rocon E, Andrade AO. On the Effect of Vibrotactile Stimulation in Essential Tremor. Healthcare (Basel). 2024 Feb 9;12(4):448. doi: 10.3390/healthcare12040448. PubMed 38391822 ↗
  • Cardoso Mendes L, Abreu Rosa de Sa A, Alves Marques I, Morere Y, de Oliveira Andrade A. RehaBEElitation: the architecture and organization of a serious game to evaluate motor signs in Parkinson's disease. PeerJ Comput Sci. 2023 Mar 15;9:e1267. doi: 10.7717/peerj-cs.1267. eCollection 2023. PubMed 37346638 ↗
  • S. Costa, I. A. Marques, A. Bevilaqua, A. Rabelo, L. Luiz, A. Cabral, N. Faustino, M. Okereke, M. Fraga Vieira e A. de Oliveira Andrade, "Biomechanical Evaluation of an Exoskeleton for Rehabilitation of Individuals with Parkinson's Disease," IRBM, vol. 44, p. 100741, February 2023
  • L. C. Mendes, A. M. Cabral, C. M. Alves, Y. Morère e A. de Oliveira Andrade, "Objective assessment of tremor in Parkinson's disease using the RehaBEElitation serious game," em 2023 IEEE International Conference on Metrology for eXtended Reality, Artificial Intelligence and Neural Engineering (MetroXRAINE), 2023
  • Mendes LC, Marques IA, Alves CM, Vieira MF, Junior EAL, Pereira AA, Naves ELM, Oliveira FHM, Bourhis G, Pino P, Morere Y, Andrade AO. Multidimensional Assessment of Individuals with Parkinson's Disease: Development and Structure Validation of a Self-Assessment Questionnaire. Healthcare (Basel). 2022 Sep 21;10(10):1823. doi: 10.3390/healthcare10101823. PubMed 36292272 ↗
  • Nobrega LR, Rocon E, Pereira AA, Andrade AO. A Novel Physical Mobility Task to Assess Freezers in Parkinson's Disease. Healthcare (Basel). 2023 Jan 31;11(3):409. doi: 10.3390/healthcare11030409. PubMed 36766984 ↗
  • L. C. Mendes, A. Moura Cabral, C. M. Alves, Y. Morere, I. A. Marques e A. de Oliveira Andrade, "Objective Evaluation of Bradykinesia Using the RehaBEElitation Serious Game," em 2022 IEEE Workshop on Complexity in Engineering (COMPENG), 2022.
  • Machado AR, Zaidan HC, Paixao AP, Cavalheiro GL, Oliveira FH, Junior JA, Naves K, Pereira AA, Pereira JM, Pouratian N, Zhuo X, O'Keeffe A, Sharim J, Bordelon Y, Yang L, Vieira MF, Andrade AO. Feature visualization and classification for the discrimination between individuals with Parkinson's disease under levodopa and DBS treatments. Biomed Eng Online. 2016 Dec 30;15(1):169. doi: 10.1186/s12938-016-0290-y. PubMed 28038673 ↗
  • Rabelo AG, Neves LP, Paixao APS, Oliveira FHM, de Souza LAPS, Vieira MF, Pereira AA, Andrade AO. Objective Assessment of Bradykinesia Estimated from the Wrist Extension in Older Adults and Patients with Parkinson's Disease. Ann Biomed Eng. 2017 Nov;45(11):2614-2625. doi: 10.1007/s10439-017-1908-3. Epub 2017 Aug 29. PubMed 28852889 ↗
  • L. C. V. Ferreira, A. G. Rabelo, M. F. Vieira, A. A. Pereira e A. d. O. Andrade, "Gait variability and symmetry assessment with inertial sensors for quantitative discrimination of Trendelenburg sign in total hip arthroplasty patients: a pilot study based on convenience sampling," Research on Biomedical Engineering, vol. 34, p. 65-72, March 2018.
  • Oliveira FHM, Machado ARP, Andrade AO. On the Use of t-Distributed Stochastic Neighbor Embedding for Data Visualization and Classification of Individuals with Parkinson's Disease. Comput Math Methods Med. 2018 Nov 4;2018:8019232. doi: 10.1155/2018/8019232. eCollection 2018. PubMed 30532798 ↗
  • National Commission for the Incorporation of Technologies in the SUS - CONITEC, Clinical Protocol and Therapeutic Guidelines Parkinson's Disease, 2017.
  • A. S. Fracassi, A. R. Gatto, S. Weber, A. A. Spadotto, P. W. Ribeiro and A. O. Schelp,
  • Woo EH, White P, Lai CW. Ergonomics standards and guidelines for computer workstation design and the impact on users' health - a review. Ergonomics. 2016 Mar;59(3):464-75. doi: 10.1080/00140139.2015.1076528. Epub 2015 Sep 24. PubMed 26224145 ↗
  • J. F. Cecato, J. M. Montiel, D. Bartholomeu and J. E. Martinelli,

Individual participant data

Plan to share: Yes — The data will be anonymised, stored in a safe and international plataform (Zenodo - https://github.com/NIATS-UFU). Only information that can be used to identify the subjects will be shared.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Starting 6 months after publication

Access criteria: Researchers that wish to have access to the data can request access at https://github.com/NIATS-UFU. Full access will be granted for research purposes.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06536348
Lead sponsor
Federal University of Uberlandia
Collaborators
Núcleo de Inovação e Avaliação Tecnológica em Saúde, Ambulatório de Doença de Parkinson e Distúrbios do Movimento do Hospital de Clínicas de Uberlândia, Associação Parkinson Goiás, Centro Universitário Araguaia (UniAraguaia), Laboratório de Análise de Movimento e Processamento de Sinais
Responsible party
Adriano de Oliveira Andrade (Professor, Federal University of Uberlandia) — Principal investigator
First posted
Aug 2, 2024
Start date
Jan 1, 2025
Primary completion
Oct 1, 2034 (estimated)
Completion
Oct 1, 2034 (estimated)
Last update
May 19, 2026

Study contacts

Adriano Andrade, PhD
Contact
adriano@ufu.br
+55 34 3239-4761
Adriano Andrade, PhD
Contact
adriano@ufu.br
+ 34 3239-4761
Adriano Andrade, PhD
principal investigator · Federal University of Uberlandia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion